BR0007613A - Aplicação de imidazo[1,5-a]-pirido[3,2-e]-pirazinonascomo medicamento - Google Patents

Aplicação de imidazo[1,5-a]-pirido[3,2-e]-pirazinonascomo medicamento

Info

Publication number
BR0007613A
BR0007613A BR0007613-9A BR0007613A BR0007613A BR 0007613 A BR0007613 A BR 0007613A BR 0007613 A BR0007613 A BR 0007613A BR 0007613 A BR0007613 A BR 0007613A
Authority
BR
Brazil
Prior art keywords
pyrazinones
pyrido
imidazo
medicine
application
Prior art date
Application number
BR0007613-9A
Other languages
English (en)
Inventor
Norbert Hoefgen
Stefan Szelenyi
Marx Degenhard
Ute Egerland
Original Assignee
Dresden Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/de
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/de
Application filed by Dresden Arzneimittel filed Critical Dresden Arzneimittel
Publication of BR0007613A publication Critical patent/BR0007613A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Patente de Invenção: "APLICAçãO DEIMIDAZO[1,5-A]-PIRIDO[3,2-E]-PIRAZINONAS COMOMEDICAMENTO". A invenção refere-se ao emprego deimidazo[1,5-al-pirido[3,2-e]-pirazinonas da fórmula (1) comoinibidores da fosfodiesterase 5 para a terapia da disfunção erétil(impotência), ao emprego de imidazo[1,5-a]-pirido[3,2-e]-pirazinonasda fórmula (1) como inibidores duais da fosfodiesterase 3 e dafosfodiesterase 5 para a terapia da insuficiência cardíaca, dahipertonia pulmonar e doenças vasculares, que ocorrem junto comuma pequena hemorragia e processos para a sua preparação.
BR0007613-9A 1999-01-20 2000-01-14 Aplicação de imidazo[1,5-a]-pirido[3,2-e]-pirazinonascomo medicamento BR0007613A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (de) 1999-01-20 1999-01-20 Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
DE1999161302 DE19961302A1 (de) 1999-12-18 1999-12-18 Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
PCT/EP2000/000260 WO2000043392A2 (de) 1999-01-20 2000-01-14 Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel

Publications (1)

Publication Number Publication Date
BR0007613A true BR0007613A (pt) 2001-10-30

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007613-9A BR0007613A (pt) 1999-01-20 2000-01-14 Aplicação de imidazo[1,5-a]-pirido[3,2-e]-pirazinonascomo medicamento

Country Status (23)

Country Link
EP (1) EP1144410A2 (pt)
JP (1) JP2002535330A (pt)
KR (1) KR20010101603A (pt)
CN (1) CN1344268A (pt)
AR (1) AR022318A1 (pt)
AU (1) AU2291200A (pt)
BG (1) BG105714A (pt)
BR (1) BR0007613A (pt)
CA (1) CA2296224A1 (pt)
CO (1) CO5190700A1 (pt)
CZ (1) CZ20012627A3 (pt)
EA (1) EA200100792A1 (pt)
EE (1) EE200100377A (pt)
HU (1) HUP0105132A3 (pt)
ID (1) ID29790A (pt)
IL (1) IL144156A0 (pt)
IS (1) IS5987A (pt)
LT (1) LT2001078A (pt)
LV (1) LV12793B (pt)
NO (1) NO20013334D0 (pt)
SK (1) SK10322001A3 (pt)
TR (1) TR200102121T2 (pt)
WO (1) WO2000043392A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EP1461022A2 (en) * 2001-12-17 2004-09-29 ALTANA Pharma AG Use of selective pde5 inhibitors for treating partial and global respiratory failure
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
FR2835741B1 (fr) * 2002-02-12 2006-05-05 Oreal Nouveaux coupleurs 6-alcoxy-2,3-diaminopyridine utiles pour la teinture des fibres keratiniques
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
EP1786428B1 (en) * 2004-08-17 2012-05-16 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
US8299080B2 (en) * 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
JP2011505366A (ja) 2007-11-30 2011-02-24 ワイス・エルエルシー ホスホエステラーゼ１０の阻害剤としてのアリールおよびヘテロアリール縮合イミダゾ［１，５−ａ］ピラジン
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
EP2906562B1 (en) 2011-10-10 2016-10-05 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
JP5842640B2 (ja) * 2012-01-31 2016-01-13 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤
WO2016022836A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
WO2016022825A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
SI3865484T1 (sl) 2015-07-07 2024-05-31 H. Lundbeck A/S Zaviralec pde9 z imidazo pirazinonsko hrbtenico za zdravljenje perifernih bolezni
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
BG105714A (en) 2002-02-28
EP1144410A2 (de) 2001-10-17
CZ20012627A3 (cs) 2002-01-16
LV12793B (lv) 2002-05-20
EE200100377A (et) 2002-10-15
CA2296224A1 (en) 2000-07-20
AR022318A1 (es) 2002-09-04
HUP0105132A2 (hu) 2002-05-29
LV12793A (lv) 2002-02-20
TR200102121T2 (tr) 2002-01-21
CN1344268A (zh) 2002-04-10
ID29790A (id) 2001-10-11
NO20013334L (no) 2001-07-05
IS5987A (is) 2001-06-29
WO2000043392A3 (de) 2000-09-28
SK10322001A3 (sk) 2002-07-02
IL144156A0 (en) 2002-05-23
WO2000043392A2 (de) 2000-07-27
KR20010101603A (ko) 2001-11-14
EA200100792A1 (ru) 2002-10-31
JP2002535330A (ja) 2002-10-22
AU2291200A (en) 2000-08-07
NO20013334D0 (no) 2001-07-05
HUP0105132A3 (en) 2002-12-28
LT2001078A (en) 2002-08-26
CO5190700A1 (es) 2002-08-29

Similar Documents

Publication Publication Date Title
BR0007613A (pt) Aplicação de imidazo[1,5-a]-pirido[3,2-e]-pirazinonascomo medicamento
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
ATE297208T1 (de) Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
HRP20130406T1 (hr) Medikamenti s aktivnošä†u prema receptoru hm74a
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
HUP0401104A3 (en) Beta-aminoacyl tetrahydroimidazo[1,2-a]pyrazines and tetrahydrotriazolo[4,3-a]pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes and pharmaceutical compositions containing them
WO2001030381A3 (de) Verwendung von csf-1-inhibitoren
BR0211450A (pt) Método terapêutico
EP0249735A3 (en) Pharmaceutical preparations comprising as active agent 2-phenyl-1.2-benzisoselenazol-3(2h)-one, for the treatment of diseases caused by oxidative stress
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
BR0109163A (pt) Uso de pirido[3,2-e]-pirazinonas como inibidores da fosfodieterase 5, para terapia de disfunção erétil
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
RS20050858A (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
MY138883A (en) Use of asiatic acid for treatment of cencer
FR2795646B1 (fr) Article manufacture pour un usage pharmaceutique humain
WO2000072823A8 (en) Preparations for the application of anti-inflammatory agents
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
AR029189A1 (es) Uso de un inhibidor de fosfodiesterasa 4 y un corticoesteroide antiinflamatorio en forma combinada, separadamente o separadamente secuencial para la preparacion de un medicamento
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
HUP0301915A2 (hu) Sildenafil és egyéb PDE5 inhibitor hatású vegyületek alkalmazása korai magömlés kezelésére szolgáló gyógyszerkészítmény elżállítására
WO2001070951A3 (de) Mittel zur diagnose und therapie viraler erkrankungen
HN2001000204A (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]